Clinical trials: Infection and Inflammatory Reaction
Chronic Hepatitis C
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or…
- Trial name
- JKB122 (NCT02293941)
- Testing
- JKB-122 5mg, JKB-122 15mg, JKB-122 35mg
- Where
- 14 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Feeding Behavior, Late-Onset Neonatal Sepsis
Effectiveness of Oral Immunotherapy Among Preterm Babies
The aim of the study is to assess the effectiveness of OIT with colostrum on the feeding behavior and Clinical Outcome of Late-onset sepsis and Necrotizing enterocolitis
- Trial name
- NCT03633500
- Testing
- Sterile water, Breastmilk
- Where
- Kuwait
- Volunteers
- 48 people
- Sponsor
- Al Adan Hospital Kuwait
Breast Implant; Complications, Infection or Inflammation
Histological Analysis of AlloMend® Acellular Dermal Matrix Used in Breast Implant Surgeries
This is a prospective, histologic analysis of biopsied tissue obtained from participants who have undergone a pre-pectoral breast reconstruction or augmentation surgery with expander placement and AlloMend® Acellular Dermal…
- Trial name
- NCT05744414
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AlloSource
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin Disease, Infectious
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intended to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating…
- Trial name
- DART (NCT02991131)
- Testing
- Tedizolid (Sivextro, BAY1192631), Linezolid
- Where
- 3 sites in Mexico, Russia and 1 more
- Volunteers
- 108 people
- Sponsor
- Bayer
Major Cutaneous Abscess, Cellulitis
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
- Conditions
- Major Cutaneous Abscess, Cellulitis, Erysipelas
- Trial name
- NCT01519778
- Testing
- TR701 FA
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacteremia, Septicemia
Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay
Prospective study at Duke University Hospital comparing the Karius Infectious Disease Diagnostic Sequencing Assay to blood culture results in admitted patients with bacteremia/septicemia.
- Trial name
- NCT02988414
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Karius, Inc.
Sepsis
Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis
The purpose of this clinical investigation is to evaluate the integration of data from the CPC12S telemonitoring device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor into a single system for the…
- Trial name
- IRHIS (NCT07595848)
- Testing
- CPC12S Telemonitoring System with Temperature/Humidity Sensor, IDRO Sweat Lactate Sensor
- Volunteers
- 360 people
- Sponsor
- Check Point R & D Ltd
COVID-19
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with…
- Trial name
- Mir-Age (NCT04393038)
- Testing
- ABX464
- Where
- 30 sites in Belgium, Brazil and 6 more
- Volunteers
- 509 people
- Sponsor
- Abivax S.A.
Surgical Site Infection, Thrombosis
Tumescent Anesthesia Antibiotic Delivery (TAAD)
This is a multicenter randomized clinical trial (RCT) comparing two modes of antibiotic delivery: Control: Intravenous Antibiotic Delivery (IVAD) Treatment: IVAD + TAAD The Food \& Drug Administration (FDA) has approved our…
- Conditions
- Surgical Site Infection, Thrombosis, Sepsis
- Trial name
- TAAD (NCT03226626)
- Testing
- Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD, SubQKath
- Volunteers
- 330 people
- Sponsor
- HK Surgical, Inc.
Septicemia
Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device When Collected Through Peripheral Intravenous Catheters
This is a randomized, open label study to evaluate the Initial Specimen Diversion Device (ISDD) in reducing the contamination rate in blood culture analysis.
- Trial name
- NCT02093494
- Testing
- Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP), Peripheral Intravenous Catheters (PIVC)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Magnolia Medical Technologies, Inc.
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Sepsis
Performance and Impact of the Sepsis ImmunoScore
The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.
- Trial name
- NCT07543497
- Testing
- Sepsis ImmunoScore
- Volunteers
- 5,000 people
- Sponsor
- Prenosis, Inc.
Septicemia
Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device
This is a matched, open label study to evaluate the Initial Specimen Diversion Device (ISDD) in reducing the contamination rate in blood culture analysis.
- Trial name
- NCT02102087
- Testing
- Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP)
- Where
- United States
- Volunteers
- 971 people
- Sponsor
- Magnolia Medical Technologies, Inc.
Staphylococcal Infections, Bacteremia
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
The purpose of this study is to establish the tolerability of treatment with human lactoferrin 1-11 peptide (hLF1-11) administered intravenously as a single dose given for 10 consecutive days, to patients with bacteremia due to…
- Trial name
- LIST (NCT00509847)
- Testing
- human lactoferrin peptide 1-11
- Where
- Netherlands
- Sponsor
- AM-Pharma
Sepsis
Effect of SRT2379 on Endotoxin-Induced Inflammation
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice.
- Trial name
- NCT01262911
- Testing
- SRT2379
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Low Gelsolin, Trauma
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels…
- Conditions
- Low Gelsolin, Trauma, Infection, Burns
- Trial name
- NCT00671307
- Testing
- rhu-pGelsolin
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Critical Biologics Corporation
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Sepsis
Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis
The primary objective of this study is to test whether a fluid resuscitation protocol guided by non-invasive hemodynamic measures reduces the progression of organ dysfunction (defined by an increase in the Serial Organ Failure…
- Trial name
- COMMIT (NCT01484106)
- Testing
- Fluid Resuscitation, Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Cheetah Medical Inc.